Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates | Taiwan News | Jan. 8, 2026 21:30

Xilio Therapeutics, a clinical-stage biotechnology company focused on masked immuno-oncology therapies, announced key corporate developments, strengthened financial resources, and outlined upcoming milestones that position the company for significant progress in 2026 and 2027.

Highlights

• Raised $35.8 million in gross proceeds from Series B warrant exercises, extending the anticipated cash runway into the second quarter of 2027.
• Reached a development milestone for a masked antibody-based program under its collaboration with AbbVie.
• Nominated a development candidate for a wholly owned masked T cell engager program targeting CLDN18.2.
• Appointed Sara M. Bonstein as chair of the board of directors.

Leadership Update

Xilio named Sara M. Bonstein as chair of its board, succeeding Paul Clancy following his retirement. Bonstein has been a board member since 2021 and brings extensive experience leading finance, strategy, and operations in the biotechnology sector. She currently serves as chief financial officer of Insmed, Inc., and previously held roles of increasing responsibility at Eli Lilly & Company and Johnson & Johnson. She holds a B.S. in finance and an M.B.A.

Company leadership noted that the appointment comes as Xilio builds on momentum from its masking technology, key partnerships, and advancing pipeline. The company expressed appreciation for Clancy’s leadership and contributions over the past five years.

Corporate Updates

In January 2026, Xilio reported receiving $35.8 million in gross proceeds from the exercise of Series B warrants issued in connection with a June 2025 follow-on public offering. The exercises included full participation by Coastlands Capital, Frazier Life Sciences, and Gilead Sciences, Inc.

The company also:

• Achieved a development milestone under its collaboration, license, and option agreement with AbbVie related to a masked antibody-based immunotherapy program.
• Nominated a development candidate for its masked T cell engager targeting CLDN18.2, a tumor-associated antigen with broad relevance across gastric, pancreatic, esophageal, and lung cancers.

Anticipated Milestones

• Submit an investigational new drug (IND) application for XTX501 in mid-2026.
• Report initial Phase 1 data for XTX501 in the second half of 2027, subject to U.S. FDA IND clearance.
• Nominate a development candidate for the STEAP1 masked T cell engager (with co-stimulation) in the first half of 2026.
• Advance at least two masked T cell engager programs into IND-enabling studies and submit INDs in 2027.
• Deliver the Phase 1/2 option data package to Gilead for the efarindodekin alfa program in the first half of 2027.

Financial Guidance

As of December 31, 2025, Xilio estimates cash and cash equivalents of approximately $137.5 million, inclusive of $35.8 million in gross proceeds received in the fourth quarter of 2025 from Series B warrant exercises. Based on current operating plans, the company expects this cash position to fund operating expenses and capital expenditures into the second quarter of 2027.

The cash information above is preliminary, unaudited, and based on management estimates for the year ended December 31, 2025. It is not a comprehensive statement of financial results, may change, and has not been audited or reviewed by the company’s independent registered public accounting firm.

About Xilio Therapeutics

Xilio Therapeutics is developing masked immuno-oncology therapies designed to localize anti-tumor activity within the tumor microenvironment and potentially improve the therapeutic index compared to conventional I-O treatments. The company’s pipeline includes novel, masked molecules such as bispecifics and T cell engagers intended to reduce systemic side effects while maintaining anti-tumor potency.

Cautionary Note Regarding Forward-Looking Statements

This article includes forward-looking statements, including expectations, plans, timelines, and anticipated milestones for Xilio’s programs; the potential of its platform and product candidates; the timing of data readouts and regulatory interactions; the timing and receipt of potential payments under collaborations; estimates of cash and cash runway; and business strategy and outlook. Forward-looking statements are based on current assumptions and involve risks and uncertainties that could cause actual results to differ materially. These risks include, among others, general market and geopolitical conditions; the initiation, conduct, timing, and results of preclinical studies and clinical trials; delays or challenges in development; supply and manufacturing risks; regulatory actions and feedback; protection of intellectual property; the ability to secure additional funding; and the maintenance of collaborations. Forward-looking statements reflect the company’s views only as of the date of this article, and the company disclaims any obligation to update such statements except as required by law.